Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative ClaimsPublished: April 3rd 2025 | Updated:
- Resource Utilization With Insulin Pump Therapy for Type 2 Diabetes Mellitus
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
3
New WHO Report Sounds Alarm on Antimicrobial Resistance
4
Pediatric Atopic Dermatitis Treatment Selection: Biologics vs Nonsteroidal Topical Therapies
5
